FOLH1 and prostate carcinoma: Review of twenty-three peer-reviewed articles revealed promising results for the use of PSMA PET/CT-derived radiomics in the prediction of biopsy Gleason score, adverse pathology, and treatment outcomes for prostate cancer (PC).